Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.

Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. doi: 10.1007/s00432-019-02931-1. Epub 2019 May 20.

PMID:
31111215
2.

Treatment of acute myeloid leukaemia in elderly patients.

Reikvam H, Dalgaard J, Johansen S, Tvedt THA, Bruserud Ø.

Tidsskr Nor Laegeforen. 2019 Apr 26;139(8). doi: 10.4045/tidsskr.18.0775. Print 2019 May 7. Norwegian.

3.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
4.

Immunosuppression And Immunotargeted Therapy In Acute Myeloid Leukemia - The Potential Use Of Checkpoint Inhibitors In Combination With Other Treatments.

Leufven E, Bruserud O.

Curr Med Chem. 2019 Mar 24. doi: 10.2174/0929867326666190325095853. [Epub ahead of print]

PMID:
30907305
5.

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects - an overview.

Skaadel H, Bruserud Ø.

Expert Rev Hematol. 2019 Feb;12(2):119-128. doi: 10.1080/17474086.2019.1570126. Epub 2019 Jan 28.

PMID:
30689456
6.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L.

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

PMID:
30679386
7.

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Grønningsæter IS, Bartaula-Brevik S, Bruserud Ø.

Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073.

8.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.

Aasebø E, Hernandez-Valladares M, Selheim F, Berven FS, Brenner AK, Bruserud Ø.

Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

9.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

10.

S100 Proteins in Acute Myeloid Leukemia.

Brenner AK, Bruserud Ø.

Neoplasia. 2018 Dec;20(12):1175-1186. doi: 10.1016/j.neo.2018.09.007. Epub 2018 Oct 23. Review.

11.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Reikvam H, Skavland J, Gullaksen SE, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT.

Case Rep Hematol. 2018 Sep 23;2018:2045985. doi: 10.1155/2018/2045985. eCollection 2018.

12.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Tvedt THA, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud Ø.

Int J Mol Sci. 2018 Sep 22;19(10). pii: E2886. doi: 10.3390/ijms19102886.

13.

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.

Nepstad I, Hatfield KJ, Tvedt THA, Reikvam H, Bruserud Ø.

Cancers (Basel). 2018 Sep 14;10(9). pii: E332. doi: 10.3390/cancers10090332.

14.

Oral Tongue Malignancies in Autoimmune Polyendocrine Syndrome Type 1.

Bruserud Ø, Costea DE, Laakso S, Garty BZ, Mathisen E, Mäkitie A, Mäkitie O, Husebye ES.

Front Endocrinol (Lausanne). 2018 Aug 17;9:463. doi: 10.3389/fendo.2018.00463. eCollection 2018.

15.

Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases.

Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H.

Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29.

PMID:
30159896
16.

Francisella tularensis bacteraemia causing multi-organ failure.

Hansen BA, Tilseth R, Finjord T, Bruserud Ø.

Oxf Med Case Reports. 2018 Aug 25;2018(9):omy067. doi: 10.1093/omcr/omy067. eCollection 2018 Sep.

17.

Immunological heterogeneity of healthy peripheral blood stem cell donors - preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation.

Bruserud Ø, Melve GK, Gedde-Dahl T, Tvedt THA.

Expert Rev Hematol. 2018 Oct;11(10):757-759. doi: 10.1080/17474086.2018.1511420. Epub 2018 Aug 20. No abstract available.

PMID:
30126308
18.

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.

Grønningsæter IS, Ahmed AB, Vetti N, Johansen S, Bruserud Ø, Reikvam H.

Clin Pract. 2018 Jun 7;8(2):1061. doi: 10.4081/cp.2018.1061. eCollection 2018 Mar 28.

19.

Successful eradication of leptomeningeal plasma cell disease.

Bruserud Ø, Hansen BA, Vetti N, Johansen S, Reikvam H.

Oxf Med Case Reports. 2018 Jul 3;2018(7):omy038. doi: 10.1093/omcr/omy038. eCollection 2018 Jul.

20.

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood.

Rundgren IM, Bruserud Ø, Ryningen A, Ersvær E.

J Immunol Methods. 2018 Oct;461:53-62. doi: 10.1016/j.jim.2018.06.003. Epub 2018 Jun 12.

PMID:
29906454
21.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.

Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.

PMID:
29889583
22.

Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Mosevoll KA, Johansen S, Wendelbo Ø, Nepstad I, Bruserud Ø, Reikvam H.

Front Med (Lausanne). 2018 May 22;5:147. doi: 10.3389/fmed.2018.00147. eCollection 2018. Review.

23.

Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

Melve GK, Ersvaer E, Eide GE, Kristoffersen EK, Bruserud Ø.

Front Immunol. 2018 May 2;9:845. doi: 10.3389/fimmu.2018.00845. eCollection 2018.

24.

Autonomous dysfunction in Lyme neuroborreliosis. A case report.

Hansen BA, Finjord T, Bruserud Ø.

Clin Case Rep. 2018 Mar 22;6(5):901-903. doi: 10.1002/ccr3.1494. eCollection 2018 May.

25.

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients.

Johansen S, Kollsete Gjelberg H, Ahmed AB, Bruserud Ø, Reikvam H.

Case Rep Oncol Med. 2018 Feb 28;2018:7697283. doi: 10.1155/2018/7697283. eCollection 2018.

26.

Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia.

Mosevoll KA, Skrede S, Markussen DL, Fanebust HR, Flaatten HK, Aßmus J, Reikvam H, Bruserud Ø.

Front Immunol. 2018 Apr 6;9:691. doi: 10.3389/fimmu.2018.00691. eCollection 2018.

27.

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.

Bartaula-Brevik S, Lindstad Brattås MK, Tvedt THA, Reikvam H, Bruserud Ø.

Expert Opin Investig Drugs. 2018 Apr;27(4):377-387. doi: 10.1080/13543784.2018.1459562. Epub 2018 Apr 4. Review.

PMID:
29611449
28.

Hypomagnesemia in critically ill patients.

Hansen BA, Bruserud Ø.

J Intensive Care. 2018 Mar 27;6:21. doi: 10.1186/s40560-018-0291-y. eCollection 2018. Review.

29.

The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis.

Melve GK, Ersvaer E, Paulsen Rye K, Bushra Ahmed A, Kristoffersen EK, Hervig T, Reikvam H, Hatfield KJ, Bruserud Ø.

Cytotherapy. 2018 May;20(5):740-754. doi: 10.1016/j.jcyt.2018.02.366. Epub 2018 Mar 22.

PMID:
29576502
30.

A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Tvedt THA, Hovland R, Tsykunova G, Ahmed AB, Gedde-Dahl T, Bruserud Ø.

Clin Exp Immunol. 2018 Jul;193(1):130-141. doi: 10.1111/cei.13124. Epub 2018 Apr 1.

PMID:
29513361
31.

Oral microbiota in autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.

J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. eCollection 2018.

32.

Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers.

Reikvam H, Grønningsæter IS, Mosevoll KA, Lindås R, Hatfield K, Bruserud Ø.

Front Immunol. 2018 Jan 24;8:1979. doi: 10.3389/fimmu.2017.01979. eCollection 2017.

33.

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.

Nepstad I, Reikvam H, Brenner AK, Bruserud Ø, Hatfield KJ.

Int J Mol Sci. 2018 Jan 27;19(2). pii: E382. doi: 10.3390/ijms19020382.

34.

Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.

Wangen R, Aasebø E, Trentani A, Døskeland SO, Bruserud Ø, Selheim F, Hernandez-Valladares M.

Int J Mol Sci. 2018 Jan 19;19(1). pii: E296. doi: 10.3390/ijms19010296.

35.

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Johansen S, Brenner AK, Bartaula-Brevik S, Reikvam H, Bruserud Ø.

Int J Mol Sci. 2018 Jan 15;19(1). pii: E251. doi: 10.3390/ijms19010251. Review.

36.

Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.

Forthun RB, Aasebø E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT.

J Proteomics. 2018 Feb 20;173:32-41. doi: 10.1016/j.jprot.2017.11.014. Epub 2017 Nov 21.

PMID:
29175091
37.

Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.

Aasebø E, Bartaula-Brevik S, Hernandez-Valladares M, Bruserud Ø.

Expert Rev Hematol. 2018 Jan;11(1):13-24. doi: 10.1080/17474086.2018.1407239. Epub 2017 Nov 23. Review.

PMID:
29168399
38.

Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1.

Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.

Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.

39.

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.

Reikvam H, Hovland R, Forthun RB, Erdal S, Gjertsen BT, Fredly H, Bruserud Ø.

BMC Cancer. 2017 Sep 6;17(1):630. doi: 10.1186/s12885-017-3620-y.

40.

Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins.

Fishman D, Kisand K, Hertel C, Rothe M, Remm A, Pihlap M, Adler P, Vilo J, Peet A, Meloni A, Podkrajsek KT, Battelino T, Bruserud Ø, Wolff ASB, Husebye ES, Kluger N, Krohn K, Ranki A, Peterson H, Hayday A, Peterson P.

Front Immunol. 2017 Aug 16;8:976. doi: 10.3389/fimmu.2017.00976. eCollection 2017.

41.

Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.

Bruserud Ø, Aasebø E, Hernandez-Valladares M, Tsykunova G, Reikvam H.

Expert Opin Drug Discov. 2017 Oct;12(10):1053-1065. doi: 10.1080/17460441.2017.1356818. Epub 2017 Jul 27. Review.

PMID:
28748730
42.

Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.

Hernandez-Valladares M, Vaudel M, Selheim F, Berven F, Bruserud Ø.

Expert Rev Proteomics. 2017 Aug;14(8):649-663. doi: 10.1080/14789450.2017.1352474. Epub 2017 Jul 27. Review.

PMID:
28693350
43.

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

Tvedt THA, Ersvaer E, Tveita AA, Bruserud Ø.

Front Immunol. 2017 Jun 8;8:667. doi: 10.3389/fimmu.2017.00667. eCollection 2017. Review.

44.

The constitutive protease release by primary human acute myeloid leukemia cells.

Honnemyr M, Bruserud Ø, Brenner AK.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1985-1998. doi: 10.1007/s00432-017-2458-7. Epub 2017 Jun 19.

PMID:
28631213
45.

A prospective observational study on effects of fever on red cell transfusion outcome.

Wendelbo Ø, Netland Opheim E, Felli Lunde TH, Bruserud Ø, Hervig T, Reikvam H.

Vox Sang. 2017 Jul;112(5):484-486. doi: 10.1111/vox.12526. Epub 2017 May 18.

PMID:
28516477
46.

CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.

47.

Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.

Brenner AK, Tvedt TH, Nepstad I, Rye KP, Hagen KM, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2017 Apr;21(4):357-369. doi: 10.1080/14728222.2017.1300255. Epub 2017 Mar 3.

PMID:
28281897
48.

Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia.

Hernandez-Valladares M, Aasebø E, Selheim F, Berven FS, Bruserud Ø.

Proteomes. 2016 Aug 22;4(3). pii: E24. doi: 10.3390/proteomes4030024. Review.

49.

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.

Brenner AK, Nepstad I, Bruserud Ø.

Front Immunol. 2017 Feb 9;8:106. doi: 10.3389/fimmu.2017.00106. eCollection 2017.

50.

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells.

Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ.

Oncotarget. 2017 Jan 17;8(3):5638-5639. doi: 10.18632/oncotarget.14676. No abstract available.

Supplemental Content

Loading ...
Support Center